Nachrichten zur Soleno Therapeutics Aktie

Soleno Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 7, 2025, at 4:30 PM ET

REDWOOD CITY, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company…

Soleno Therapeutics: Das Biopharmazie-Unternehmen erhält wichtige FDA-Zulassung für ein Medikaments zur Behandlung einer seltenen genetischen Störung

Soleno ist ein biopharmazeutisches Unternehmen, das neuartige Therapeutika zur Behandlung seltener Krankheiten entwickelt. Mit der FDA-Zulassung von VYKAT XR,…

Soleno Therapeutics im Pivotal-Point-Check: Stifel sieht „Blockbuster-Chance“ durch die Zulassung von Vykat XR zur Behandlung des Prader-Willi-Syndroms!

Soleno Therapeutics hat einen Meilenstein auf dem Markt für seltene Krankheiten erreicht. Die Behandlung mit Diazoxid-Cholin zielt darauf ab,…

Soleno Therapeutics: In No Rush To Join Buying Frenzy Despite Vykat Approval

…

Soleno Therapeutics: PDUFA Extension May Be An Opportunity, But Not For Me

…

Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments

…

Why Soleno Therapeutics Stock Blasted 9% Higher Today

The companys Prader-Willi treatment inched closer to FDA approval.…

Soleno Therapeutics Announces Regulatory Update on DCCR (diazoxide choline) Extended-Release Tablets to Treat Prader-Willi Syndrome

REDWOOD CITY, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical…

Soleno Therapeutics: 2 New Catalysts To Bring Forth Change For PWS Patients

…

Soleno Therapeutics CFO sells over $298k in company stock By Investing.com

Soleno Therapeutics CFO sells over $298k in company stock…

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical…

Soleno Therapeutics Stands with the Prader-Willi Syndrome Community

This Prader-Willi Syndrome Awareness Day, May 15, join Soleno Therapeutics in sharing messages of hope and kindness for the Prader-Willi…

Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock

REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a…

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical…

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

REDWOOD CITY, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical…

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical…

dpa-AFX ProFeed